PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share






Zack DeFilipp, MD - Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TGK865. CME/MOC credit will be available until March 20, 2025.

Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Incyte Corporation.

Disclosure information is available at the beginning of the video presentation.


fyyd: Podcast Search Engine
share








 March 27, 2024  16m